SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

79.55 1.66

Visão Geral

Variação de preço das ações

24h

Atual

Mín

77.8

Máximo

79.95

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

33.602

67.147

EPS

0.834

Margem de lucro

19.539

Funcionários

1,950

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+8.85% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

79M

4.1B

Abertura anterior

77.89

Fecho anterior

79.55

Sentimento de Notícias

By Acuity

50%

50%

186 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 23:08 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 23:07 UTC

Ganhos

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:20 UTC

Ganhos

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 de abr. de 2026, 23:27 UTC

Conversa de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 de abr. de 2026, 23:22 UTC

Ganhos

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 de abr. de 2026, 23:20 UTC

Conversa de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 de abr. de 2026, 22:52 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:33 UTC

Ganhos

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 de abr. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 de abr. de 2026, 22:05 UTC

Ganhos

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 21:57 UTC

Ganhos

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 de abr. de 2026, 21:55 UTC

Ganhos

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 de abr. de 2026, 21:53 UTC

Ganhos

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

8.85% parte superior

Previsão para 12 meses

Média 86.75 EUR  8.85%

Máximo 90 EUR

Mínimo 83.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

186 / 347 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat